Cetrorelix

What is Cetrorelix?

Cetrorelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, sold as Cetrotide, used during IVF and ICSI cycles to stop the body from releasing its own luteinizing hormone (LH) before the eggs are ready to collect. It is a modified copy of natural GnRH with amino acid substitutions at positions 1, 2, 3, 6 and 10, which converts the native hormone from an agonist into a competitive blocker of its own receptor. Clinically that difference is the whole point: a GnRH agonist like leuprolide or buserelin has to overstimulate the pituitary for one to two weeks before it desensitizes, so an agonist IVF protocol starts weeks before stimulation does. Cetrorelix blocks the receptor directly from the first injection, so it can be started on day 5 or 6 of stimulation and stopped the day the trigger shot is given — typically five or six injections instead of a month of pituitary shutdown. FDA approved Cetrotide in August 2000, and the antagonist protocol it enabled has since become the default approach to controlled ovarian stimulation in much of the world.

What Cetrorelix Is Investigated For

Cetrorelix has exactly one approved use — inhibiting premature LH surges in women undergoing controlled ovarian stimulation — and the evidence for it is unusually clean. The pivotal European Cetrorelix Study Group trial (Albano 2000) randomized 188 women to cetrorelix and 85 to the agonist buserelin, and found that cetrorelix cut both the number of hMG ampoules and the number of stimulation days required, with an LH and progesterone rise in only 3 of 188 women (1.6%), and fertilization, cleavage and pregnancy rates comparable to the agonist arm. The class-level picture is captured by the 2016 Cochrane review of 73 RCTs in 12,212 women: GnRH antagonists produce no detectable difference in live birth versus the long agonist protocol (OR 1.02, 95% CI 0.85-1.23) while substantially lowering the incidence of ovarian hyperstimulation syndrome (OR 0.61, 95% CI 0.51-0.72). The 2025 Cochrane network meta-analysis, built on 338 trials and 59,086 women, reaches the same conclusion with more conservative numbers — little to no difference in live birth or ongoing pregnancy (RR 0.95), a modest OHSS reduction (RR 0.88), and slightly fewer oocytes retrieved. That trade — the same birth rate, meaningfully less OHSS, fewer injections, a shorter cycle, marginally fewer eggs — is why antagonist protocols displaced long agonist protocols as the default. Everything outside fertility is historical: cetrorelix was tested in uterine fibroids, endometriosis and benign prostatic hyperplasia, produced real signals in each, and was never approved for any of them.

History & Discovery

Cetrorelix was developed as SB-75 in the laboratory of Andrew Schally, whose group at Tulane and the New Orleans VA had been building GnRH analogues since the 1970s — work that followed directly from the isolation and sequencing of GnRH for which Schally shared the 1977 Nobel Prize in Physiology or Medicine. The problem Schally's group was attacking is the central problem of the antagonist class. GnRH agonists had become clinically useful by the mid-1980s, but they work through a paradox: they overstimulate the pituitary GnRH receptor until it desensitizes, which means a one-to-two-week stimulatory 'flare' and weeks of lead time before suppression is achieved. A direct antagonist would avoid all of that. The first- and second-generation antagonists, however, caused dose-dependent histamine release from mast cells severe enough to produce systemic allergic reactions, and the class stalled. Cetrorelix was the compound that solved enough of that problem to reach the clinic. The third-generation antagonists retained high receptor affinity and metabolic stability while cutting histamine release to a level tolerable for short courses of treatment. Early human work through the early and mid-1990s — Klingmüller's hormonal response studies in 1993, Felberbaum's phase 2 work in women with tubal infertility in 1995 — established that the compound suppressed gonadotropins rapidly and reversibly, and that pituitary responsiveness was preserved rather than ablated. The decisive trial was the prospective randomized phase 3 European Cetrorelix Study Group study published in 2000, which put 188 women on cetrorelix against 85 on the agonist buserelin. The cetrorelix arm needed significantly fewer hMG ampoules and fewer days of stimulation, only 1.6% of women had an LH and progesterone rise, and pregnancy outcomes matched. FDA approved Cetrotide on 11 August 2000 under NDA 021197, originally to Asta Medica and now marketed by EMD Serono; ganirelix had been approved in the United States thirteen months earlier. Two cetrorelix presentations were approved: a 0.25 mg vial for daily dosing and a 3 mg vial for the single-administration protocol, in which one larger dose covers the surge-risk window. The 3 mg presentation has since been discontinued in the United States, and the daily multiple-dose protocol is what survives in practice. The non-fertility programs are the road not taken. Through the late 1990s and 2000s cetrorelix was tested in uterine fibroids, endometriosis, and benign prostatic hyperplasia, in each case with a depot pamoate formulation designed for infrequent dosing. The fibroid work reported fast, substantial shrinkage; the BPH program ran a positive double-blind dose-ranging trial. None reached approval. The strategic space those programs targeted has since been occupied by the oral small-molecule GnRH antagonists — elagolix, relugolix, linzagolix — which deliver comparable axis suppression without an injection, and by degarelix for the oncology setting, where its much lower histamine-release profile made chronic dosing viable in a way cetrorelix never was.

How It Works

Natural GnRH is released in pulses from the hypothalamus and tells the pituitary to make LH and FSH. Cetrorelix is a redesigned copy of that hormone that plugs into the same receptor but does not switch it on. Because it simply occupies the receptor, the effect is immediate — LH falls within hours — and it reverses as soon as the drug clears. In IVF that means the body cannot release the LH surge that would ovulate the eggs before they can be collected, without having to shut the pituitary down for weeks in advance.

Cetrorelix is a synthetic decapeptide (Ac-D-Nal(2)1-D-Cpa2-D-Pal(3)3-Ser4-Tyr5-D-Cit6-Leu7-Arg8-Pro9-D-Ala10-NH2, molecular weight 1431.06 as the anhydrous free base) that competitively and reversibly binds the pituitary GnRH receptor. Substitutions at positions 1, 2, 3, 6 and 10 — including D-amino acids and non-natural residues — convert the native agonist into a high-affinity antagonist and simultaneously confer resistance to the peptidases that give endogenous GnRH its two-to-four-minute half-life. Receptor occupancy blocks Gq/11-coupled signaling and the downstream gonadotropin release, so serum LH falls within hours of the first dose and FSH follows, with no desensitization step and therefore no flare. Suppression is dose-dependent and fully reversible on withdrawal, which is why pituitary function returns promptly once dosing stops at the trigger. Cetrorelix is a third-generation antagonist: the earlier generations were limited by histamine release from mast cells, and while cetrorelix is far better in this respect than the first-generation compounds, an ex vivo human skin study found it still releases substantially more histamine than degarelix, which is part of why degarelix rather than cetrorelix became the antagonist suitable for chronic daily-equivalent dosing in prostate cancer. Elimination is mixed, with meaningful renal clearance — the basis for the contraindication in severe renal impairment.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cetrorelix:

• 01Whether the modestly lower oocyte yield consistently seen with antagonist protocols translates into any difference in cumulative live birth across all fresh and frozen transfers from a single stimulation — the outcome that actually matters to patients, and one most trials were not designed to measure.
• 02Whether any patient subgroup — predicted poor responders in particular, in whom antagonist protocols show a higher rate of cancellation for poor response — does genuinely better on a long agonist protocol, or whether that signal reflects selection rather than biology.
• 03Whether cetrorelix and ganirelix differ in any clinically meaningful way; the only large comparison is retrospective and single-centre, and no randomized head-to-head trial has been conducted despite 25 years of parallel use.
• 04How antagonist protocols interact with progestin-primed ovarian stimulation and freeze-all strategies, which have changed the context in which the original antagonist-versus-agonist comparisons were made.
• 05Whether the discontinued depot cetrorelix indications — fibroids and BPH — failed on commercial grounds or would have failed on efficacy; the published dose-ranging data were positive, and the question was never resolved by a confirmatory trial.
• 06Long-term health outcomes in children conceived in antagonist cycles beyond the obstetric and neonatal data gathered in the original programs.

Forms & Administration

Subcutaneous injection only, into the lower abdomen around the navel. Cetrorelix is supplied as a sterile lyophilized powder that must be reconstituted with the supplied sterile water immediately before use — the 0.25 mg vial also contains 54.8 mg of mannitol. After reconstitution the solution is drawn up and injected with a fine needle; the kit includes separate needles for reconstitution and for injection. Patients are routinely taught to self-administer after instruction, and the injection site should be rotated. The 3 mg single-dose vial, used in the historical single-administration protocol, has been discontinued in the United States; only the 0.25 mg presentation remains marketed. All injectable peptides should be administered under the guidance of a qualified healthcare provider — in the case of cetrorelix, inside a monitored stimulation cycle with ultrasound and hormone tracking.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Cetrorelix is approved only for inhibiting premature LH surges in women undergoing controlled ovarian stimulation, and only as part of a monitored assisted-reproduction cycle with ultrasound and hormone tracking. It has no standalone or wellness use.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Cetrorelix Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies of clinical significance have been established for cetrorelix, and the short course of treatment limits exposure. The interactions that matter are pharmacodynamic rather than pharmacokinetic, and are built into the protocol by design. Cetrorelix is given alongside gonadotropins — recombinant FSH, hMG or urinary FSH — whose dose is titrated against ovarian response; adding cetrorelix to an ongoing stimulation characteristically allows the gonadotropin requirement to fall, which was one of the findings of the original phase 3 program. Concomitant GnRH agonist use makes no sense pharmacologically, since the two act at the same receptor in opposite directions. The hCG trigger works downstream at the LH receptor and is unaffected by GnRH receptor blockade, but a GnRH-agonist trigger is possible only in an antagonist cycle, because the pituitary has not been desensitized — this is a genuine therapeutic interaction and one of the practical reasons antagonist protocols reduce OHSS risk in high responders. Oral contraceptive pre-treatment is sometimes used for scheduling and alters the starting hormonal milieu rather than interacting with cetrorelix directly.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions